公开(公告)号：US20220380353A1

公开(公告)日：2022-12-01

申请号：US17870955

申请日：2022-07-22

申请人： SUMITOMO PHARMA CO., LTD.

发明人： Hitoshi WATANABE ,  Yoshiaki ISOBE ,  Hidenori KIMURA ,  Yuji FUJIWARA

IPC分类号： C07D405/14 ,  A61K31/352 ,  A61K31/4192 ,  A61K31/4709 ,  A61K31/519 ,  C07D311/22 ,  C07D405/04 ,  C07D471/04 ,  A61P25/28 ,  A61P27/04

摘要： The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X=Y-Z, X-Y=Z, or X-Y-Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

公开(公告)号：US20240124429A1

公开(公告)日：2024-04-18

申请号：US18510883

申请日：2023-11-16

申请人： Sumitomo Pharma Co., Ltd.

发明人： Hitoshi WATANABE ,  Shuya YAMADA ,  Katsushi KITAHARA ,  Mariko KOBAYASHI

IPC分类号： C07D405/14 ,  A61P25/16 ,  C07D413/14 ,  C07D491/08

CPC分类号： C07D405/14 ,  A61P25/16 ,  C07D413/14 ,  C07D491/08

摘要： The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

公开(公告)号：US20230365589A1

公开(公告)日：2023-11-16

申请号：US18026187

申请日：2021-09-17

申请人： Sumitomo Pharma Co., Ltd. ,  CARNA BIOSCIENCES, INC.

发明人： Shingo TOJO ,  Daisuke URABE ,  Hitoshi WATANABE ,  Wataru KAWAHATA ,  Hideki MORIYAMA ,  Yuko ASAMITSU

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： The present invention provides an amine derivative having a DYRK-inhibiting activity and represented by formula (1):




wherein A1, A2, L1, L2, X, Z, R1 and R4 are as defined in the description,

or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20130303535A1

公开(公告)日：2013-11-14

申请号：US13895089

申请日：2013-05-15

申请人： Dainippon Sumitomo Pharma Co., Ltd.

发明人： Katsunori TSUBOI ,  Yusuke YAMAI ,  Hitoshi WATANABE ,  Hironori KINOSHITA

IPC分类号： C07D471/04 ,  C07D405/04 ,  C07D405/14 ,  C07D235/14

CPC分类号： C07D471/04 ,  C07D235/14 ,  C07D405/04 ,  C07D405/14

摘要： The invention provides a compound for the treatment or prophylaxis of pathology involving SNS, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like. The compound is represented by formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is a hydrogen atom or the like, L is a single bond, —O— or the like, R2 is a phenyl group or the like, X is a carbon atom or a nitrogen atom, and R3, R4, R5a, R5b, R6 and R7 are each independently a substituted or unsubstituted alkyl group or the like:

摘要翻译： 本发明提供了用于治疗或预防涉及SNS的疾病的化合物，特别是诸如神经性疼痛，伤害性疼痛，排尿困难，多发性硬化症等疾病。 该化合物由式（1）表示或其药学上可接受的盐表示，其中R1是氢原子等，L是单键，-O-等，R2是苯基等，X是 碳原子或氮原子，R3，R4，R5a，R5b，R6和R7各自独立地为取代或未取代的烷基等：